ALEC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.09M

-96.16%

-0.378

+1791.65%

0.00

-100%

-0.415

+1.22%

0.00

-100%

-0.395

+31.67%

Estimates Revision

The market is revising Downward the revenue expectations for Alector, Inc. (ALEC) for FY2025, with the revenue forecasts being adjusted by -4.29% over the past three months. During the same period, the stock price has changed by -38.41%.

Revenue Estimates for FY2025

Revise Downward

-4.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.72%

In Past 3 Month

Stock Price

Go Down

-38.41%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 2.06 USD with a low forecast of 0.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

5 Hold

2 Sell

Hold

Current: 0.000

Low

0.75

Averages

2.06

High

5.00

Current: 0.000

Low

0.75

Averages

2.06

High

5.00

Morgan Stanley

Underweight

maintain

2026-01-08

New

Reason

Morgan Stanley

Price Target

2026-01-08

New

maintain

Underweight

Reason

Morgan Stanley raised the firm's price target on Alector to 90c from 75c and keeps an Underweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

Morgan Stanley

NULL -> Underweight

downgrade

2025-11-17

Reason

Morgan Stanley

Price Target

2025-11-17

downgrade

NULL -> Underweight

Reason

Morgan Stanley lowered the firm's price target on Alector to 75c from $1.50 and keeps an Underweight rating on the shares. The firm, which is updating its model to account for the Phase 3 INFRONT-3 trial evaluating latozinemab failing to meet its co-primary endpoint, now includes revenues for AL101 in Alzheimer's disease but in a "heavily discounted" fashion, the analyst tells investors.

H.C. Wainwright

Buy

downgrade

$10 -> $5

2025-10-22

Reason

H.C. Wainwright

Price Target

$10 -> $5

2025-10-22

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Alector to $5 from $10 and keeps a Buy rating on the shares. The firm removed AL001 from the stock's valuation following the INFRONT-3 data miss. However, it believes Alector's AL137, AL050, and ADP064-ABC offer "diversified, large market optionality, creating multiple potential paths to upside."

Mizuho

Outperform

Neutral

downgrade

2025-10-22

Reason

Mizuho

Price Target

2025-10-22

downgrade

Outperform

Neutral

Reason

Mizuho downgraded Alector to Neutral from Outperform with a price target of $1.50, down from $3.50. The firm cites the negative Pahe 3 data for latozinemab for the downgrade. Alector has other pipeline candidates in development, but there is high risk associated with developing therapeutics for Alzheimer's disease, the analyst tells investors in a research note.

TD Cowen

Yaron Werber

Buy -> Hold

downgrade

2025-10-22

Reason

TD Cowen

Yaron Werber

Price Target

2025-10-22

downgrade

Buy -> Hold

Reason

TD Cowen analyst Yaron Werber downgraded Alector to Hold from Buy without a price target. The Phase 3 INFRONT-3 miss ends the company's latozinemab program and the shares have few near-term catalysts, the analyst tells investors in a research note. The firm says that while Alector's 49% headcount cut "is step in right direction," its cash burn is high with runway to 2027.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

$NULL

2025-10-22

Reason

Cantor Fitzgerald

Price Target

$NULL

2025-10-22

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded Alector to Neutral from Overweight without a price target after the company's INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly positive benefit. Alector's other programs are too early to value, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Alector Inc (ALEC.O) is -0.96, compared to its 5-year average forward P/E of -7.11. For a more detailed relative valuation and DCF analysis to assess Alector Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.11

Current PE

-0.96

Overvalued PE

9.43

Undervalued PE

-23.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.64

Current EV/EBITDA

0.78

Overvalued EV/EBITDA

7.88

Undervalued EV/EBITDA

-9.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.50

Current PS

87.80

Overvalued PS

37.36

Undervalued PS

-6.37

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ALEC News & Events

Events Timeline

No data

News

5.0

2025-12-12Globenewswire

Alector Appoints Neil Berkley as CFO, Strengthening Leadership Amid Strategic Growth

5.0

2025-12-12Newsfilter

Alector Appoints Neil Berkley as CFO to Drive Biotech Strategy

5.0

2025-12-12NASDAQ.COM

Alector Appoints Neil Berkley as CFO

People Also Watch

Frequently Asked Questions

What is Alector Inc (ALEC) stock price today?

The current price of ALEC is 1.86 USD — it has increased 5.08 % in the last trading day.

What is Alector Inc (ALEC)'s business?

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

What is the price predicton of ALEC Stock?

What is Alector Inc (ALEC)'s revenue for the last quarter?

Alector Inc revenue for the last quarter amounts to 3.26M USD, decreased -78.75 % YoY.

What is Alector Inc (ALEC)'s earnings per share (EPS) for the last quarter?

Alector Inc. EPS for the last quarter amounts to -0.34 USD, decreased -20.93 % YoY.

What changes have occurred in the market's expectations for Alector Inc (ALEC)'s fundamentals?

How many employees does Alector Inc (ALEC). have?

Alector Inc (ALEC) has 238 emplpoyees as of January 10 2026.

What is Alector Inc (ALEC) market cap?

Today ALEC has the market capitalization of 203.02M USD.